X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer

Adjuvant docetaxel without prednisone failed to improve biochemical disease-free survival in men with intermediate- or high-risk prostate cancer who have undergone radical radiotherapy with androgen deprivation therapy, according to results of the Scandinavian Prostate Cancer Group’s multinational phase III SPCG-13 trial.

Read more.

source: Cancer Network